Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes

Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes

<i>Purpose</i>: The aim of this study was to evaluate the effect of switching treatment in eyes with neovascular age-related macular degeneration (nAMD) and treatment intervals of ≤6 weeks to brolucizumab. <i>Methods</i>: In this prospective series, eyes with persisting retin...

Full description

Bibliographic Details
Main Authors:	Christof Haensli, Isabel B. Pfister, Justus G. Garweg
Format:	Article
Language:	English
Published:	MDPI AG 2021-06-01
Series:	Journal of Clinical Medicine
Subjects:	brolucizumab ranibizumab aflibercept anti-VEGF neovascular age-related macular degeneration visual acuity
Online Access:	https://www.mdpi.com/2077-0383/10/12/2666

Similar Items

Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: a randomized trial in Indian patients
by: Sanjay Kumar Mishra, et al.
Published: (2022-07-01)

Intravitreal Brolucizumab in Patients with Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
by: Ashwin Gupta, et al.
Published: (2022-01-01)

Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab
by: Rachel Hui Fen Lim, et al.
Published: (2017-03-01)

Brolucizumab in Pretreated Neovascular Age-Related Macular Degeneration: Case Series, Systematic Review, and Meta-Analysis
by: Christof Hänsli, et al.
Published: (2023-03-01)

Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab
by: Flora Elwes, et al.
Published: (2018-01-01)

Real-World Experience Using Intravitreal Brolucizumab Alone or in Combination with Aflibercept in the Management of Neovascular Age-Related Macular Degeneration
by: Mehta N, et al.
Published: (2023-02-01)

Patient adherence to therapy after switch to aflibercept from bevacizumab or ranibizumab for treatment-refractory neovascular age-related macular degeneration
by: Simon D Archambault, et al.
Published: (2024-01-01)

Efficacy of Aflibercept and Ranibizumab in the treatment of diabetic macular edema
by: Bing Wu, et al.
Published: (2023-08-01)

Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ranibizumab
by: Nixon DR, et al.
Published: (2018-01-01)

Real-World Experience with Brolucizumab Compared to Aflibercept in Treatment-Naïve and Therapy-Refractory Patients with Diabetic Macular Edema
by: Anne Rübsam, et al.
Published: (2024-03-01)

Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
by: Kaiser SM, et al.
Published: (2021-09-01)

Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
by: Koike N, et al.
Published: (2019-07-01)

Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy
by: Nicola Ferrante, et al.
Published: (2022-04-01)

Aflibercept Treatment Results and Association with Baseline Characteristics in Cases of Newly Diagnosed Neovascular Age-Related Macular Degeneration
by: Pelin Kıyat, et al.
Published: (2021-06-01)

Evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab
by: Nixon DR, et al.
Published: (2017-04-01)

Temporary Vitelliform Regression After Intravitreal Ranibizumab Injection for Macular Neovascularization Complicating Best Disease
by: Fayed A
Published: (2022-10-01)

Comparison of the regressive effects of aflibercept and brolucizumab on pigment epithelial detachment
by: Ryo Mukai, et al.
Published: (2022-09-01)

Case Series on Initial Responses to Intravitreal Brolucizumab in Patients with Recalcitrant Chronic Wet Age-Related Macular Degeneration
by: Avaylon J, et al.
Published: (2020-05-01)

Comparison of ranibizumab and bevacizumab in neovascular age-related macular degeneration
by: Huseyin Serdarogullari, et al.
Published: (2014-05-01)

Comparison of the effectiveness of various protocols for the transition to aflibercept with tachyphylaxis for ranibizumab in patients with neovascular AMD
by: A. N. Kulikov, et al.
Published: (2018-11-01)

Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab
by: Daniel Sanju Narayan, et al.
Published: (2015-01-01)

Efficacy of Aflibercept versus Ranibizumab in the treatment of diabetic macular edema
by: Xiu-Xian Wang, et al.
Published: (2021-12-01)

Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye
by: Emilia Maggio, et al.
Published: (2022-09-01)

Comparative study between ranibizumab and aflibercept in the management of macular edema caused by diabetes mellitus in age group more than 40 years
by: Abd El-Magid M Tag El-Din
Published: (2019-01-01)

Intravitreal Aflibercept Therapy in Intravitreal Bevacizumab/Ranibizumab Treatment-resistant Exudative Age-related Macular Degeneration
by: Neslihan Sevimli, et al.
Published: (2023-09-01)

Biosimilar versus InnovAtor MoLecule of RAnibizumab in Neovascular Age-Related MaCular DEgeneration (The BALANCE Trial): Real-World Evidence
by: Chakraborty D, et al.
Published: (2023-04-01)

Anatomical and functional responses to single brolucizumab injection in neovascular age-related macular degeneration patients not responding to antiangiogenics: a case series
by: Silvio Zuccarini, et al.
Published: (2022-03-01)

Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
by: Garweg JG
Published: (2019-07-01)

Biomarkers as Predictive Factors of Anti-VEGF Response
by: Miriam Bobadilla, et al.
Published: (2022-04-01)

A novel small molecule anti-VEGF drug Brolucizumab in the treatment of neovascular age-related macular degeneration
by: Tong Wu, et al.
Published: (2022-05-01)

Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration
by: Levon M. Khachigian, et al.
Published: (2023-02-01)

Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better
by: Khanani AM, et al.
Published: (2019-02-01)

Long-term outcomes of Ranibizumab treatment in neovascular age-related macular degeneration
by: Burak Simsek, et al.
Published: (2018-02-01)

Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects
by: Justus G. Garweg, et al.
Published: (2023-01-01)

Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept
by: Pallavi Tyagi, et al.
Published: (2018-06-01)

Managing Neovascular Age-Related Macular Degeneration in Clinical Practice: Systematic Review, Meta-Analysis, and Meta-Regression
by: Daniele Veritti, et al.
Published: (2022-01-01)

Comparative Safety of Bevacizumab, Ranibizumab, and Aflibercept for Treatment of Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Network Meta-Analysis of Direct Comparative Studies
by: Anna A. Plyukhova, et al.
Published: (2020-05-01)

Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration
by: Joseph M. Coney, et al.
Published: (2023-02-01)

Two Year Study of Aflibercept and Ranibizumab Intravitreal Therapy in Patients with Wet AMD
by: Dorota Luksa, et al.
Published: (2021-11-01)

One-year outcome of intravitreal aflibercept injection for age-related macular degeneration resistant to ranibizumab: rapid morphologic recovery and subsequent visual improvement
by: Hirakata T, et al.
Published: (2016-05-01)